Somru BioScience Revenue and Competitors
Estimated Revenue & Valuation
- Somru BioScience's estimated annual revenue is currently $6.4M per year.
- Somru BioScience's estimated revenue per employee is $155,000
Employee Data
- Somru BioScience has 41 Employees.
- Somru BioScience grew their employee count by 24% last year.
Somru BioScience's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Director Corporate Services | Reveal Email/Phone |
4 | President | Reveal Email/Phone |
5 | Research Technician | Reveal Email/Phone |
6 | Principal Investigator | Reveal Email/Phone |
7 | Account Manager / Logistics Leader | Reveal Email/Phone |
Somru BioScience Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $30M | 155 | -5% | $132.7M | N/A |
#2 | $10.9M | 70 | -5% | $2M | N/A |
#3 | $15.7M | 101 | 5% | N/A | N/A |
#4 | $11M | 71 | 8% | N/A | N/A |
#5 | $123.9M | 571 | -11% | $94.5M | N/A |
#6 | $22.5M | 320 | 0% | $845.8M | N/A |
#7 | $9.8M | 41 | -68% | $494.1M | N/A |
#8 | $443.8M | 821 | 11% | $371.2M | N/A |
#9 | $33.6M | 217 | 19% | N/A | N/A |
#10 | $100M | 461 | 8% | $871.5M | N/A |
What Is Somru BioScience?
The rise of biosimilars has provided challenges and opportunities in equal measure for biotechnology, biopharmaceutical and bioanalytical contract research organizations (CROs). Somru BioScience has developed a portfolio of reagents, tools, solutions and a knowledge database that will enable companies to capitalize on biosimilar opportunities. We provide comprehensive expertise and solutions to reduce both the time and cost of your biosimilar development programs
keywords:N/AN/A
Total Funding
41
Number of Employees
$6.4M
Revenue (est)
24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $9M | 45 | 10% | N/A |
#2 | $7.8M | 50 | 43% | N/A |
#3 | $13.6M | 94 | 47% | N/A |
#4 | $26.2M | 97 | 3% | N/A |
#5 | $22.9M | 104 | 44% | N/A |